A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy.
Sichun XiangRongbin ShenJingjing XiangNi ZhuJianyou GuJianping ShenYu ZhangHangping GePublished in: Expert opinion on drug safety (2024)
The ibrutinib-obinutuzumab combo has the highest risk of infection, atrial fibrillation, and myelosuppression, and the ibrutinib-lenalidomide combo has the highest risk of pyrexia. However, the ibrutinib-venetoclax combo has a lower risk of hemorrhage than monotherapy.
Keyphrases
- chronic lymphocytic leukemia
- combination therapy
- adverse drug
- atrial fibrillation
- heart failure
- emergency department
- clinical trial
- oral anticoagulants
- open label
- percutaneous coronary intervention
- randomized controlled trial
- drug induced
- coronary artery disease
- low dose
- multiple myeloma
- chronic myeloid leukemia
- mitral valve